Pharmesis International Ltd. (SGX:BFK)
Singapore · Delayed Price · Currency is SGD 0.1250
0.00 (0.00%)
At close: Aug 14, 2026
Pharmesis International Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 28.42 | 43.75 | 67.65 | 45.64 | 50.37 | 52.77 |
Revenue Growth | -35.05% | -35.32% | 48.24% | -9.40% | -4.55% | 12.01% |
Gross Profit Gross Profit Growth | 9.53 | 15.84 | 24.15 | 20.82 | 24.01 | 25 |
Operating Income Operating Income Growth | -8.34 | -5.31 | 2.02 | -2.8 | -2.53 | 1.06 |
Net Income Net Income Growth | -7.29 | -4.3 | 8.28 | -4.96 | -3.56 | 1.17 |
Earnings Per Share EPS Growth | -0.23 | -0.14 | 0.28 | -0.19 | -0.15 | 0.05 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Eliminations Eliminations Growth | -13.13 | -25.27 | -16.22 | -10.07 | - | - |
TCM Formulated Drugs/IP Rental TCM Formulated Drugs/IP Rental Growth | 19.6 | 26.05 | 18.84 | 34.9 | 36.72 | 37.51 |
Distribution Distribution Growth | 13.53 | 26.54 | 21.03 | 9.74 | - | - |
Western Drugs / TCH Procurement Western Drugs / TCH Procurement Growth | 8.42 | 16.43 | 44 | 11.07 | 13.65 | 15.26 |
Total Total Growth | 28.42 | 43.75 | 67.65 | 45.64 | 50.37 | 52.77 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 5.35 | 4.31 | 4.6 | 9.48 | 19.72 | 13.98 |
Total Debt Total Debt Growth | 15.42 | 15.7 | 16.26 | 16.52 | 16.53 | 17.14 |
Net Cash (Debt) Net Cash Growth | -10.07 | -11.38 | -11.66 | -7.05 | 3.19 | -3.16 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -0.32 | -0.36 | -0.39 | -0.27 | 0.14 | -0.14 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 4.4 | 2.65 | -2.38 | -11.58 | 6.56 | 0.65 |
Capital Expenditures CapEx Growth | 0.01 | -0.29 | -1.17 | -0.59 | -0.24 | -1.58 |
Free Cash Flow Free Cash Flow Growth | 4.41 | 2.36 | -3.54 | -12.17 | 6.33 | -0.93 |
Free Cash Flow Growth | 86.70% | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 33.53% | 36.20% | 35.70% | 45.61% | 47.67% | 47.38% |
Operating Margin | -29.33% | -12.13% | 2.99% | -6.13% | -5.02% | 2.01% |
Pretax Margin | -24.57% | -9.13% | 12.47% | -10.65% | -6.27% | 4.01% |
Profit Margin | -25.65% | -9.83% | 12.24% | -10.86% | -7.07% | 2.22% |
FCF Margin | 15.51% | 5.40% | -5.24% | -26.66% | 12.56% | -1.76% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | 11.78 | - | - | 13.89 |
P/FCF Ratio | 4.72 | 27.75 | - | - | 2.04 | - |
PS Ratio | 0.73 | 1.50 | 1.44 | 0.32 | 0.26 | 0.31 |